上海君實生物醫藥科技股份有限公司 SHANGHALIUNSHI BIOSCIENCES CO., LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability) (Stock code: 1877)



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

28 March 2024

Dear Shareholders

New Arrangements on Dissemination of Corporate Communications

INTRODUCTION

Pursuant to new Rule 2.07A¹ of the Rules (the "Listing Rules") Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") and the articles of association of Shanghai Junshi Biosciences Co., Ltd. * (the "Company"), the Company will disseminate the future corporate communications of the Company (the "Corporate Communications" ²) to its Shareholders³ electronically and only send Corporate Communications in printed form to the Shareholders upon request.

In this connection, the following arrangements will come into effect on 28 March 2024.

ARRANGEMENTS

1. Actionable Corporate Communications⁴

The Company will send the Actionable Corporate Communications to its Shareholders individually in electronic form by email. If the Company does not possess the email address of a Shareholder or the email address provided is not functional⁵, the Company will send the Actionable Corporate Communication in printed form together with a request form for soliciting the Shareholder's functional email address to facilitate electronic dissemination of Actionable Corporate Communications in the future.

2. Corporate Communications

The Company will make the Corporate Communications available on its website (www.junshipharma.com) and the Stock Exchange's website (www.hkexnews.hk).

The Company will not send a notice of publication of the Website Version⁶ of Corporate Communications to its Shareholders. The Shareholders are encouraged to proactively monitor the availability of all future Corporate Communications on the websites and access the Website Version of Corporate Communications by themselves.

3. Provision of Shareholder's Email Address to the Company

In support of electronic communication by email, the Company recommends its Shareholders to complete the online form by scanning the above QR Code which is valid until 27 May 2024. Should the Shareholders, for any reason, have difficulty in gaining access to the online form, they may provide the Company with their email address at any time in the future by reasonable notice in writing to the Company's branch share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to 1877-ecom@hk.tricorglobal.com.

It is the responsibility of the Shareholders to provide an email address that is functional. If the Company does not possess the email address of a Shareholder or the email address provided is not functional, the Company will act according to the above arrangements. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

4. Request for Corporate Communications and Actionable Corporate Communications in printed form

For those Shareholders who wish to receive a printed version of all future Corporate Communications and Actionable Corporate Communications) or, if for any reason, have difficulty in gaining access to the Company's website, the Company will, upon receipt of request in writing by the Shareholder to the Company's branch share registrar in Hong Kong at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong or by email to 1877-ecom@hk.tricorglobal.com], send future Corporate Communications and/or the relevant Corporate Communications (as the case may be) to such Shareholders in printed form free of charge.

Details of the arrangements (i) for dissemination of Corporate Communications and (ii) for requesting printed version of Corporate Communications are published under the section "Investor Relation" in the Company's website (www.junshipharma.com). For any queries in relation to this letter, please call the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited, at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. from Monday to Friday, excluding Hong Kong public holidays, or by sending an email to 1877-ecom@hk.tricorglobal.com.

By order of the Board

Shanghai Junshi Biosciences Co., Ltd. *

Mr. Xiong Jun

Chairman

* for identification purposes only

¹ With effect from 31 December 2023.

² Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; and (g) a proxy form.

³ Holder(s) of the share(s) of the Company.

⁴ Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

⁵ It is the responsibility of a Shareholder to provide an email address that is functional. The Company will be considered to have complied with the Listing Rules if it sends Actionable Corporate Communications to the email address provided by a Shareholder without receiving any "non-delivery message".

⁶ The version of Corporate Communications being published, in both English and Chinese, on the Company's website.